Tag: ACC.25
FFR-guided PCI catches up to CABG at five years in FAME 3 study
Five-year results of the FAME 3 trial, comparing fractional flow reserve (FFR)-guided percutaneo...
ACC.25: Low-dose colchicine seen to reduce coronary plaque progression in EKSTROM trial
Low-dose colchicine (0.5mg per day) significantly reduced the total plaque volume progression by 1.1...
ACC.25: ECLIPSE study results support routine use of intravascular imaging during PCI of calcified lesions, investigators say
Using intravascular imaging (IVI) to guide drug-eluting stent implantation during complex percut...
ACC.25: TEER with Triclip reduces heart failure hospitalisation versus medical therapy among TR patients in TRILUMINATE trial
Patients undergoing transcatheter edge-to-edge repair (TEER) using the Triclip (Abbott) system f...
ACC.25: ALIGN-AR reports positive outcomes with dedicated TAVI device for aortic regurgitation
Data from 500 patients treated for aortic regurgitation with the Trilogy (JenaValve) transcathet...
ACC.25: Evolut Low Risk trial shows comparable rates of all-cause mortality and stroke with TAVI and surgery at five years
Latest data from the Evolut Low Risk trial demonstrate a numerically lower rate of all-cause mor...
ACC.25: Cerebral embolic protection found not to reduce stroke in BHF PROTECT TAVI trial
Use of cerebral embolic protection with the Sentinel (Boston Scientific) device during transcath...
ACC.25: Semaglutide improves walk distance for PAD patients with diabetes
Semaglutide significantly improved maximal walking distance in people with symptomatic periphera...
ACC.25: Bentracimab can reverse bleeding complications linked to ticagrelor
An investigational monoclonal antibody called bentracimab can safely and effectively reverse pot...
ACC.25: Rivaroxaban “a viable alternative to warfarin” in STEMI patients with left-ventricular thrombus
At three months of follow-up, patients hospitalised for a serious heart attack who were treated ...
